Regulation of thyroid cell proliferation by TSH and other factors: a critical evaluation of in vitro models
- PMID: 11588145
- DOI: 10.1210/edrv.22.5.0444
Regulation of thyroid cell proliferation by TSH and other factors: a critical evaluation of in vitro models
Abstract
TSH via cAMP, and various growth factors, in cooperation with insulin or IGF-I stimulate cell cycle progression and proliferation in various thyrocyte culture systems, including rat thyroid cell lines (FRTL-5, WRT, PC Cl3) and primary cultures of rat, dog, sheep and human thyroid. The available data on cell signaling cascades, cell cycle kinetics, and cell cycle-regulatory proteins are thoroughly and critically reviewed in these experimental systems. In most FRTL-5 cells, TSH (cAMP) merely acts as a priming/competence factor amplifying PI3K and MAPK pathway activation and DNA synthesis elicited by insulin/IGF-I. In WRT cells, TSH and insulin/IGF-I can independently activate Ras and PI3K pathways and DNA synthesis. In dog thyroid primary cultures, TSH (cAMP) does not activate Ras and PI3K, and cAMP must be continuously elevated by TSH to directly control the progression through G(1) phase. This effect is exerted, at least in part, via the cAMP-dependent activation of the required cyclin D3, itself synthesized in response to insulin/IGF-I. This and other discrepancies show that the mechanistic logics of cell cycle stimulation by cAMP profoundly diverge in these different in vitro models of the same cell. Therefore, although these different thyrocyte systems constitute interesting models of the wide diversity of possible mechanisms of cAMP-dependent proliferation in various cell types, extrapolation of in vitro mechanistic data to TSH-dependent goitrogenesis in man can only be accepted in the cases where independent validation is provided.
Similar articles
-
Relationship between proliferation and cell cycle-dependent Ca2+ influx induced by a combination of thyrotropin and insulin-like growth factor-I in rat thyroid cells.J Clin Invest. 1990 Nov;86(5):1548-55. doi: 10.1172/JCI114874. J Clin Invest. 1990. PMID: 1700796 Free PMC article.
-
Thyroid-stimulating hormone and insulin-like growth factor-1 synergize to elevate 1,2-diacylglycerol in rat thyroid cells. Stimulation of DNA synthesis via interaction between lipid and adenylyl cyclase signal transduction systems.J Clin Invest. 1988 Sep;82(3):1144-8. doi: 10.1172/JCI113672. J Clin Invest. 1988. PMID: 2843569 Free PMC article.
-
Differential utilization of cyclin D1 and cyclin D3 in the distinct mitogenic stimulations by growth factors and TSH of human thyrocytes in primary culture.Mol Endocrinol. 2006 Dec;20(12):3279-92. doi: 10.1210/me.2005-0515. Epub 2006 Aug 17. Mol Endocrinol. 2006. PMID: 16916940
-
Thyroid growth in vitro.Exp Clin Endocrinol. 1992;100(1-2):32-5. doi: 10.1055/s-0029-1211171. Exp Clin Endocrinol. 1992. PMID: 1468512 Review.
-
Thyrotropin-dependent proliferation of in vitro rat thyroid cell systems.Eur J Endocrinol. 2000 Aug;143(2):161-78. doi: 10.1530/eje.0.1430161. Eur J Endocrinol. 2000. PMID: 10913934 Review.
Cited by
-
Active surveillance in low risk papillary thyroid carcinoma.World J Clin Oncol. 2020 Jun 24;11(6):320-336. doi: 10.5306/wjco.v11.i6.320. World J Clin Oncol. 2020. PMID: 32874948 Free PMC article. Review.
-
Conservative management of low-risk papillary thyroid carcinoma: a review of the active surveillance experience.Thyroid Res. 2023 Mar 13;16(1):6. doi: 10.1186/s13044-023-00148-6. Thyroid Res. 2023. PMID: 36907911 Free PMC article. Review.
-
Morphological changes induced by insulin-like growth factor-I gene therapy in pituitary cell populations in experimental prolactinomas.Cells Tissues Organs. 2010;191(4):316-25. doi: 10.1159/000258701. Epub 2009 Nov 14. Cells Tissues Organs. 2010. PMID: 19923782 Free PMC article.
-
A novel partner for D-type cyclins: protein kinase A-anchoring protein AKAP95.Biochem J. 2004 Mar 1;378(Pt 2):673-9. doi: 10.1042/BJ20031765. Biochem J. 2004. PMID: 14641107 Free PMC article.
-
Association of Thyrotropin Suppression With Survival Outcomes in Patients With Intermediate- and High-Risk Differentiated Thyroid Cancer.JAMA Netw Open. 2019 Feb 1;2(2):e187754. doi: 10.1001/jamanetworkopen.2018.7754. JAMA Netw Open. 2019. PMID: 30707227 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources